FDA committees meet to investigate Testosterone Deficiency therapy
On 17 September the FDA's Bone, Reproductive and Urologic Drugs panel will convene with the Drug Safety and Risk Management committee to assess the appropriate indicated population for Testosterone Replacement Therapy and the potential for adverse cardiovascular outcomes associated with testosterone drugs. Recently judges in Chicago consolidated a number of cases brought against against Abbott and AbbVie which sell AndroGel; Eli Lilly which makes Axiron; Pfizer ( for its injectable version; and Actavis for its testosterone patch.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins